FIG. 1



FINE PARTICLE PHAGOCYTIC MACROPHAGES
MEDICAL SOLUTION SOAKING MACROPHAGES
DRUG INCLUSION FINE PARTICLES
MEDICAL SOLUTION
DRUG
MACROPHAGES
DRUG
MACROPHAGES
DRUG CONCENTRATION IN THE FINE PAETICLE
DRUG
DRUG
MACROPHAGES
MACROPHAGES

FIG. 2



FREQUENCY (%)
20
18
16
14
12
10
8
6
4
2
0
0.50
1.32
1.60
1.95
2.38
2.90
3.53
4.30
5.24
6.39
7.78
9.48
11.55
14.08
17.15
20.90
DIAMETER (μm)

FIG. 3



*; P < 0.005
RIFAMPICIN-PLGA FINE PARTICLE FORMULATION
RIFAMPICIN-CONTAINING MEDIUM
AMOUNT OF RIFAMPICIN IN NR8383 CELLS (μg/5×10^5 CELLS)
AMOUNT OF ADDED RIFAMPICIN (μg/5×10^5 CELLS/WELL/mL)
×19
0
1
2
3
4
0
10
20
30
40
50

FIG. 4



120
100
80
60
40
20
0
RELEASING RATE OF RIFAMPICIN (%)
0
5
10
15
20
25
30
TIME (DAY)
5020
5010
5005

FIG. 5



120
100
80
60
40
20
0
RELEASING RATE OF RIFAMPICIN (%)
0
5
10
15
20
25
30
TIME (DAY)
7520
7510
7505

FIG. 6




VIABILITY OF TUBERCULOSIS GERMS
0
1
2
3
4
5
0
4
24
48
96
TIME
MEDIUM
RFP
RFP-PLGA

FIG. 7


100
80
60
40
20
0
-20
CYTOTOXICITY %
□:UNTREATED WITH LIPOPOLYSACCHARIDE
■:TREATED WITH LIPOPOLYSACCHARIDE
0.1/1
0.5/1
1/1
5/1
CELL RATIO OF NR8383 TO SATO LUNG CANCER